• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Genetic Predisposition to Coronary Artery Disease: Evaluating Statin Therapy in Elder Populations From PROSPER.

作者信息

Choi Seung Hoan, Young Robin, Koyama Satoshi, Jukema J Wouter, Trompet Stella, Ford Ian, Natarajan Pradeep, Peloso Gina M

机构信息

Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.

Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.

出版信息

JACC Adv. 2025 Jan 8;4(2):101535. doi: 10.1016/j.jacadv.2024.101535. eCollection 2025 Feb.

DOI:10.1016/j.jacadv.2024.101535
PMID:39886309
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11780074/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/075f/11780074/c55029a8c51e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/075f/11780074/c55029a8c51e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/075f/11780074/c55029a8c51e/gr1.jpg

相似文献

1
Genetic Predisposition to Coronary Artery Disease: Evaluating Statin Therapy in Elder Populations From PROSPER.冠状动脉疾病的遗传易感性：评估PROSPER研究中老年人群的他汀类药物治疗
JACC Adv. 2025 Jan 8;4(2):101535. doi: 10.1016/j.jacadv.2024.101535. eCollection 2025 Feb.
2
Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting.多基因风险评分可识别出在一级预防中动脉粥样硬化负担更高且从他汀类药物治疗中获得更大相对获益的亚组。
Circulation. 2017 May 30;135(22):2091-2101. doi: 10.1161/CIRCULATIONAHA.116.024436. Epub 2017 Feb 21.
3
Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease.当代指南在管理具有高冠心病遗传风险患者方面的局限性。
J Am Coll Cardiol. 2020 Jun 9;75(22):2769-2780. doi: 10.1016/j.jacc.2020.04.027.
4
European and US Guideline-Based Statin Eligibility, Genetically Predicted Coronary Artery Disease, and the Risk of Major Coronary Events.基于欧洲和美国指南的他汀类药物适用性、遗传性预测的冠状动脉疾病与主要冠状动脉事件风险。
J Am Heart Assoc. 2024 May 7;13(9):e032831. doi: 10.1161/JAHA.123.032831. Epub 2024 Apr 19.
5
Effect of statin therapy on cardiovascular outcomes after coronary revascularization in patients ≥ 80 years of age: observations from the CREDO-Kyoto Registry Cohort-2.他汀类药物治疗对80岁及以上患者冠状动脉血运重建后心血管结局的影响：来自CREDO-Kyoto注册队列2的观察结果。
Atherosclerosis. 2014 Dec;237(2):821-8. doi: 10.1016/j.atherosclerosis.2014.10.108. Epub 2014 Nov 4.
6
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study.KIF6基因Trp719Arg多态性与他汀类药物治疗对老年患者的影响：PROSPER研究结果
Eur J Cardiovasc Prev Rehabil. 2010 Aug;17(4):455-61. doi: 10.1097/HJR.0b013e328336a0dd.
7
Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real-World Population.多基因风险评分与他汀类药物相对风险降低在真实世界人群中心肌梗死一级预防中的作用。
Clin Pharmacol Ther. 2022 Nov;112(5):1070-1078. doi: 10.1002/cpt.2715. Epub 2022 Aug 24.
8
Genetics, coronary artery disease, and myocardial revascularization: will novel genetic risk scores bring new answers?遗传学、冠状动脉疾病与心肌血运重建：新型遗传风险评分会带来新答案吗？
Indian J Thorac Cardiovasc Surg. 2018 Dec;34(Suppl 3):213-221. doi: 10.1007/s12055-017-0635-6. Epub 2018 Jan 18.
9
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.在接受恩杂鲁胺治疗的去势抵抗性前列腺癌患者中，使用他汀类药物和二甲双胍与结局的相关性：AFFIRM、PREVAIL 和 PROSPER 的荟萃分析。
Eur J Cancer. 2022 Jul;170:285-295. doi: 10.1016/j.ejca.2022.04.005. Epub 2022 May 26.
10
Genetics, its role in preventing the pandemic of coronary artery disease.遗传学在预防冠状动脉疾病大流行中的作用。
Clin Cardiol. 2021 Jun;44(6):771-779. doi: 10.1002/clc.23627. Epub 2021 May 25.

本文引用的文献

1
Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants.在超过 100 万名参与者中发现并系统地描述了冠心病的风险变异和基因。
Nat Genet. 2022 Dec;54(12):1803-1815. doi: 10.1038/s41588-022-01233-6. Epub 2022 Dec 6.
2
Risk of Coronary Artery Disease Conferred by Low-Density Lipoprotein Cholesterol Depends on Polygenic Background.低密度脂蛋白胆固醇所致冠状动脉疾病风险取决于多基因背景。
Circulation. 2021 Apr 6;143(14):1452-1454. doi: 10.1161/CIRCULATIONAHA.120.051843. Epub 2021 Mar 8.
3
The UK Biobank resource with deep phenotyping and genomic data.
英国生物银行资源库，具有深度表型和基因组数据。
Nature. 2018 Oct;562(7726):203-209. doi: 10.1038/s41586-018-0579-z. Epub 2018 Oct 10.
4
Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting.多基因风险评分可识别出在一级预防中动脉粥样硬化负担更高且从他汀类药物治疗中获得更大相对获益的亚组。
Circulation. 2017 May 30;135(22):2091-2101. doi: 10.1161/CIRCULATIONAHA.116.024436. Epub 2017 Feb 21.
5
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics.老年高危人群普伐他汀前瞻性研究（PROSPER）：筛查经验及基线特征
Curr Control Trials Cardiovasc Med. 2002 May 20;3(1):8. doi: 10.1186/1468-6708-3-8.